No Data
No Data
Volition Appoints PharmaVentures for Capture PCR and Oncology Portfolio Licensing
VolitionRX Stockholders Set Course With Key Governance Decisions
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
HENDERSON, Nev., June 27, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its
VolitionRx Files to Sell 73,263 Shares for Holders
Express News | EF Hutton Maintains Buy on VolitionRX, Maintains $4 Price Target
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and VolitionRX (VNRX)
No Data